newswire, breaking biotechnology and pharma news

Monday, September 8, 2014

GenSpera (OTCQB:GNSZ) Presents Mipsagargin (G-202) HCC Clinical Trial Update at 8th International Liver Cancer Association Conference

Biotech News Alert: GenSpera (OTCQB:GNSZ) Presents Mipsagargin (G-202) HCC Clinical Trial Update at 8th International Liver Cancer Association Conference

50% of Patients Treated with Mipsagargin had No Tumor Growth at Four Months

SAN ANTONIO - September 8, 2014 ( Biotech Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, presented the hepatocellular carcinoma (HCC), or liver cancer, Phase II clinical trial update for mipsagargin (G-202) at the 8th International Liver Cancer Association (ILCA) Conference on Saturday, September 6, 2014, in Kyoto, Japan. CEO, Craig Dionne, PhD, will discuss these results in further detail during the Company's presentation at the Rodman & Renshaw 16th Annual Global Investment Conference on Tuesday, September 9th at 12:05 p.m. Eastern.

GenSpera presented a poster containing interim results from the Phase Ib and ongoing Phase II study in HCC patients who had previously progressed on, or who were intolerant of, sorafenib, a drug co-developed and co-marketed by Bayer and Onyx Pharmaceuticals. Historically, this patient population has a median time to progression of only two months when they enter subsequent clinical trials. Impressively, 50% of patients exhibited stable disease (no tumor growth) at 4 months on study.

"Mipsagargin is differentiated from most other drugs being tested in HCC due to its well-tolerated safety profile and the significant proportion of patients that experience prolonged disease stabilization while on treatment," stated Dr. Craig Dionne, GenSpera CEO. "Liver cancer is the third largest cancer killer worldwide and is expected to represent a $1.5 billion market by 2019. We are encouraged by these early stage positive results and what they imply for our ongoing and planned Phase II clinical trials for mipsagargin in glioblastoma, prostate cancer and renal cell carcinoma patients."

Investors can view the poster at the Company website:

Rodman & Renshaw 16th Annual Global Investment Conference Details:
When: Tuesday, September 9th at 12:05 p.m. Eastern
Where: The New York Palace Hotel in New York City


To arrange a one-on-one meeting with management, please contact Steve Gersten at

About GenSpera
GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera's lead drug candidate, mipsagargin, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. Mipsagargin is therefore expected to have potential efficacy in a wide variety of tumor types.

Mipsagargin Phase II clinical trials are underway in both hepatocellular carcinoma and glioblastoma patients.

For more information, please visit the company's website: or follow us on Twitter @GenSperaNews.

Company presentations are available at:

Watch the Corporate Video:

About ILCA 2014
The 8th Annual International Liver Cancer Association Conference was held September 5-7, 2014, at the Hotel Granvia Kyoto in Kyoto, Japan. The International Liver Cancer Association (ILCA) is an international organization devoted exclusively to liver cancer research for experts from all related disciplines. Visit the ILCA website at

Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements. Investors are cautioned that statements in this press release regarding potential applications of GenSpera's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera's periodic reports filed with the Securities and Exchange Commission.

Craig Dionne, PhD, CEO
GenSpera, Inc.  (210) 479-8112                                     

Steve Gersten
Capital Markets Group

Dawn Van Zant
(800) 665 0411

Visit this company:

More info on GNSZ at Visit:

Disclaimer/Disclosure: newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: Disclosure: Genspera (GNSZ) has engaged Investor Ideas for PR and news publication effective June 18, 2014 (compensation of five thousand per month and average of eleven thousand five hundred 144 shares per month)
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: Global investors must adhere to regulations of each country.

Become an Member and access our 14 online stock directories 24/7 –biotech, mining stocks, oil and gas stocks and more... 

No comments:

Post a Comment